TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05263882
Drug: Gemcitabine combined with eribulin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur.
Study: NCT05385705
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
Study: NCT05385705
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
Study: NCT05385705
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
Study: NCT05760456
Drug: DIDALA hard capsules
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
Study: NCT05760456
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
Study: NCT06656234
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
Study: NCT06656234
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Study: NCT06405204
Drug: Co-Enzyme Q10
Normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a lipid-soluble quinone, acting as an effective antioxidant,
Study: NCT05960955
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT05960955
Drug: AK117
Normalized name: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
DrugBank: Ligufalimab (DB17542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT05960955
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion,Specified dose on specified days
Study: NCT05960955
Drug: Tegafur-gimeracil-oteracil potassium
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral,Specified dose on specified days
Study: NCT05960955
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT05960955
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion,Specified dose on specified days
Study: NCT04930783
Drug: CDX-301
Normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an injection given underneath the skin
Study: NCT04930783
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV)
Study: NCT04930783
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV)
Study: NCT04586244
Drug: retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
Study: NCT04586244
Drug: epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epacadostat will be administered daily twice daily orally up to and including day of surgery.
Study: NCT04586244
Drug: INCAGN02385
Normalized name: Anti-LAG-3 Monoclonal Antibody INCAGN02385
DrugBank: Tuparstobart (DB19118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
Study: NCT04586244
Drug: INCAGN02390
Normalized name: INCAGN02390
DrugBank: Verzistobart (DB18895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
Study: NCT06675929
Drug: BI 770371
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 770371
Study: NCT04072640
Drug: Voriconazole 200mg
Normalized name: VORICONAZOLE 200MG TAB
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
Study: NCT04072640
Drug: amphotericin B deoxycholate (0.4-0.5mg/kg/d)
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
Study: NCT04072640
Drug: Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
Normalized name: deoxycholate
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
Study: NCT04335682
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to darolutamide.
Study: NCT04335682
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized to enzalutamide.
Study: NCT04461509
Drug: 18F-PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer
Study: NCT06478017
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive 10mg/kg on Day 3 post-transplant (72 hours +/- 12 hours post-transplant)~Day 7 post-transplant (+/- 6 hours)~Day 16 (End of Week 2 after 1st dose of belatacept) post-transplant (+/- 2 days)~Day 30 (End of Week 4 after 1st dose of belatacept) post-transplant (+/- 3 days)~Day 58 (Week 8) post-transplant (+/- 3 days)~Day 86 (Week 12) post-transplant (+/- 3 days)~Patients will receive 5mg/kg Every 28 days (+/- 3 days) thereafter
Study: NCT06478017
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prograf (tacrolimus) or tacrolimus generic
Study: NCT06478017
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone
Study: NCT06613685
Drug: GS-1720
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets administered orally without regard to food
Study: NCT06613685
Drug: GS-4182
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets administered orally without regard to food
Study: NCT04442581
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04888221
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care.
Study: NCT04832438
Drug: 9-ING-41
Normalized name: ING-1
DrugBank: ING-1 (DB05831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
Study: NCT04832438
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
Study: NCT03948074
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal Cannabis Oil
Study: NCT06613685
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally without regard to food
Study: NCT05244525
Drug: Bupivacaine alone
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Study: NCT03939273
Drug: Vancomycin Oral
Normalized name: vancomycin Oral Capsule
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg thrice per day for seven days
Study: NCT03939273
Drug: Metronidazole Oral
Normalized name: metronidazole Oral Gel
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg thrice per day for seven days
Study: NCT03939273
Drug: Ciprofloxacin Pill
Normalized name: ciprofloxacin Pill
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice per day for seven days
Study: NCT03939273
Drug: Fluconazole Oral Product
Normalized name: fluconazole Oral Product
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg once per day for six days
Study: NCT05014100
Drug: Orelabrutinib tablet
Normalized name: acalabrutinib Oral Tablet
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
Study: NCT05014100
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
Study: NCT05368805
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
Study: NCT05368805
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
Study: NCT06340204
Drug: Irinotecan Hydrochloride Liposome Injection
Normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
Study: NCT04681287
Drug: inetetamab and PD-1 inhibitor combined with chemotherapy.
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued.
Study: NCT06613516
Drug: Capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib is a selective inhibitor of the kinase activity of the serine/threonine Akt/PKB pathway that may potentially provide clinical benefit over a range of therapeutic indications. Capivasertib comes in capsule form in two forms; 160mg or 200mg
Study: NCT05582499
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
Study: NCT05582499
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
Study: NCT05582499
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an anti-HER2 antibody-drug conjugate (ADC)
Study: NCT05582499
Drug: SHR-1316
Normalized name: Immunoglobulin G4 (52-glycine, 57-phenylalanine, 227-proline, 233-alanine, 234-alanine, 446-alanine), anti-(human programmed death-ligand 1) (human-mus musculus monoclonal SHR-1316 .gamma.4-chain) fusion protein with peptide linker ((ggggs)4g) fusion protein with 20-136-type II transforming growth factor .beta. receptor (human isoform 1), disulfide with (85-glutamic acid) human-mus musculus monoclonal SHR-1316 .kappa.-chain, dimer
DrugBank: Retlirafusp alfa (DB17517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an anti-programmed death ligand 1 (PD-L1) antibody
Study: NCT05582499
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an anti-programmed death-1 (PD1) antibody
Study: NCT05582499
Drug: SHR-A1921
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophoblast cell-surface antigen 2 (TROP2) ADC
Study: NCT05582499
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab
Study: NCT05582499
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab
Study: NCT05582499
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: goserelin
Study: NCT05582499
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: letrozole
Study: NCT05582499
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin paclitaxel
Study: NCT05582499
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin
Study: NCT05582499
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin
Study: NCT05582499
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
Study: NCT05582499
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tyrosine kinase inhibitors
Study: NCT05582499
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tyrosine kinase inhibitors
Study: NCT06679946
Drug: Vutrisiran
Normalized name: Vutrisiran
DrugBank: Vutrisiran (DB16699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutrisiran administered SC q3M
Study: NCT05026996
Drug: Pelacarsen
Normalized name: Pelacarsen
DrugBank: Pelacarsen (DB16284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of pelacarsen
Study: NCT05024812
Drug: fruquintinib＋toripalimab + SOX
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
Study: NCT06028594
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration
Study: NCT06028594
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration
Study: NCT06224543
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
Study: NCT04692493
Drug: targeted synthetic DMARD class
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
Study: NCT04470752
Drug: Capsaicin 1% oral solution
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin 1.0 micrograms/ml
Study: NCT05025488
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
Study: NCT06079346
Drug: OT-101
Normalized name: OT-730
DrugBank: OT-730 (DB16112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
Study: NCT06193993
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
Study: NCT05178628
Drug: Innohep
Normalized name: Innohep
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
Study: NCT05178628
Drug: Chemotherapy: Gemcitabine + Nab-Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive chemotherapy per clinical practice
Study: NCT05422911
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study: NCT05422911
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study: NCT05422911
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study: NCT04620473
Drug: Anlotinib+Capeox
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
Study: NCT05155436
Drug: Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg
Normalized name: amlodipine / telmisartan Pill
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
Study: NCT05707234
Drug: Midazolam sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.